Find Clinical Trials

Inclusion Criteria: * The inclusion criteria are: 1) Black men (self-report); 2) adult age 18 years or older; 3) Life's Essential 8 total average score \< 80; 4) English speaking; and 5) lives in Metropolitan Columbus, Ohio. Exclusion Criteria: * healthcare provider-imposed limitations on physical activity.

Inclusion Criteria: * A diagnosis of preeclampsia (defined as hypertension in combination with significant proteinuria (albumin/creatinine ratio \>8 mg/mmol, protein/creatinine ratio\>30 mg/mmol or \>2+ protein on a urinary dipstick) has been made by the attending clinician * The managing clinicians have made the assessment to proceed with expectant management. * The subject has given written consent to participate in the study. * The woman must be 18 years of age or older * The gestational age is between 22+0 weeks to 33+6 weeks with a viable fetus * The woman carries a singleton pregnancy Exclusion Criteria: * Contraindications to treatment with metformin as outlined in SmPC * Contraindications for expectant management of preeclampsia such as an immediate indication for delivery according to SFOG guidelines for preeclampsia (https://www.sfog.se/media/338533/pe-riktlinje-230214.pdf). * Type 1 Diabetes Mellitus * Current use of metformin * Known or suspected allergies against metformin * Reluctance or language difficulties that result in difficulty understanding the meaning of study participation * Unable to understand the informed consent process * Previous participation in the study * Established fetal compromise that necessitates imminent delivery (including planned delivery after 48 hours of corticosteroid treatment). This will be decided by the clinical team before expectant management is offered to the patient. * Suspicion of a major known fetal anomaly or malformation. * Renal disease or dysfunction, suggested by a creatinine level greater than or equal to 125 µmol/L or rapidly declining renal function * Known acute or chronic metabolic acidosis, including diabetic ketoacidosis * Not suitable for inclusion by the opinion of the investigator

Inclusion Criteria: * ≥18 years of age * Diagnosed with Stage I-III breast cancer, having completed primary cancer treatment (e.g., surgery, chemotherapy, radiation therapy); hormonal therapies and adjuvant targeted therapies will be permitted Exclusion Criteria: * Any injury or medical condition that would prohibit being able to safely perform exercise as indicated by the Physical Activity Readiness Questionnaire (i.e., atrial fibrillation, chest pain or angina, uncontrolled high blood pressure or hypertension, loss of balance due to dizziness in the past 12 months, or loss of consciousness in the past 12 months). * Non-English speaking

Inclusion Criteria: * PART I: Women aged 18 years or older * PART I: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure * PART I: Individuals who have previously (within the last 3 years) undergo an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign in nature * PART I: Individuals who have agreed to participate in the study and who have signed the study-specific informed consent * PART II: Women aged 18 years or older * PART II: If able to become pregnant, negative pregnancy test within 48 hours prior to MBI biopsy procedure * PART II: Individuals who have previously (within the last 3 years) undergone an MBI study and were found to have at least one breast imaging finding on MBI that was subsequently shown (through additional imaging, biopsy or follow-up) to be benign or probably benign in nature * PART II: Individuals who had recent conventional imaging work-up including either x-ray mammography, ultrasound, MBI, or MRI of the breast and are found to have at least one breast imaging finding for which biopsy is required or recommended, specifically: * Individuals who have a breast abnormality(ies) on imaging with mammography, ultrasound, MBI, or MRI (as per American College of Radiology \[ACR\] Breast Imaging Reporting and Data System \[BIRADS\] 3, or higher) and requiring imaging follow-up or biopsy confirmation * PART II: Individuals who have agreed to participate in the study and who have signed study-specific informed consent Exclusion Criteria: * PART I: Women who are pregnant * PART I: Women who are currently lactating or discontinued breastfeeding \< 2 months prior to the study * PART I: Age less than 18 years * PART I: Women with breast implant(s) in the breast containing the lesion of interest * PART I: Inability to provide informed consent * PART II: Women who are pregnant * PART II: Women who are currently lactating or discontinued breastfeeding \< 2 months prior to the study * PART II: Age less than 18 years * PART II: Women with breast implant(s) in the breast containing the lesion of interest * PART II: Women who have recently (within the last 3 months) undergone biopsy of the breast finding * PART II: Women who are scheduled for a sentinel node procedure using radioactive Tc-99m within 24 hours of MBI-guided biopsy * PART II: Patients with contraindications for core biopsy and other invasive procedures such as blood coagulation disorders, infection, or who are unwilling to discontinue use of anticoagulant medication prior to the procedure * PART II: Inability to provide informed consent * PART II: Women who have had surgery on the study breast(s) within the past 12 months

Inclusion Criteria: * Age \>18 * Female * Histologically proven diagnosis of localised, non-metastatic breast cancer * Indication for neo-adjuvant or adjuvant anthracycline and taxane chemotherapy (3 or 4 EC100 followed by 3 Docetaxel or 3 or 4 EC100 plus 9 to 12 Paclitaxel); HER-positive status is not a non-inclusion criterion. * Patient willing to be photographed to assess IFA * Fluency in French * Patient affiliated to a social security scheme * Signature of informed consent Exclusion Criteria: * History of neck pain * Pre-existing alopecia * Participation in another trial * Dermatosis of the scalp * Contraindication to scalp cooling * History of migraines, stroke or hyperthyroidism * History of scalp metastases * Sensitivity to cold, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia or post-traumatic cold dystrophy. * Malignant haemopathies * History of chemotherapy treatment * Indication for cerebral irradiation * Pregnant or breast-feeding patient * Raynaud's syndrome

Inclusion Criteria: * Presenting a depressive episode of moderate intensity according to the Diagnostic and Statistical Manual (DSM)-V * With a prescription for an antidepressant started less than 2 months before inclusion in the trial. * Whose state of health is compatible with follow-up by their GP (possibility of occasional advice from a psychiatrist). * Have Internet access at home (computer) and are able to use the digital platform. Exclusion Criteria: * Patients who are unable to complete self-questionnaires (language barrier, etc.) * Who have already undergone a psycho-education or therapeutic patient education programme regarding depression. * Whose state of health requires follow-up by a psychiatrist

Inclusion Criteria (patients): * Willingness to participate in a scientific study * Diagnosis of a psychosis spectrum disorder * Finnish language skills due to questionnaires and psychological tests being in Finnish Exclusion Criteria (patients): * Psychosis that severely deteriorates the ability to function * Cognitive problems that severely deteriorate the ability to function * Guardianship established for personal matters Inclusion Criteria (non-patient controls): * Willingness to participate in a scientific study * Self-assessed sufficient Finnish language skills due to questionnaires and psychological tests being in Finnish Exclusion Criteria (non-patient controls): * Diagnosis of a psychosis spectrum disorder * Cognitive problems that severely interferes with functioning

Inclusion Criteria: 1. speak English or Spanish 2. are at least 18 years old 3. live in the District of Columbia, Maryland, or Virginia (DMV) 4. have a child aged 4-12 years who is hospitalized due to asthma exacerbation. Exclusion Criteria: 1. . Children ages 4-12 years with chronic medical condition (other than asthma) including but not limited to diabetes, sickle cell disease, heart disease, lung disease or neurological disorder 2. . Children ages 4-12 years involved in interventions with behavioral component and/or novel asthma therapeutics will be excluded given overlap with the current intervention 3. . Children ages 4-12 years in foster care 4. . Families not residing in the DMV 5. . Caregivers who do not speak English or Spanish

Inclusion criteria: 1. Adult, age ≥ 40 and \< 80 years 2. Participant must meet at least one of following sets of conditions: 1. BMI ≥ 27 kg/m² OR 2. BMI ≥ 25 kg/m² AND presence of i) pre-diabetes (HbA1C ≥ 5.7) or ii) type 2 diabetes mellitus (T2DM), as defined by the American Diabetes Association (ADA) clinical practice recommendations. The ADA definition of T2DM is applicable if one of the following criteria is met: * Presence of diabetes symptoms (polyuria, polydipsia, polyphagia, increased fatigue, weight loss, blurred vision) and casual plasma glucose ≥ 200 mg/dL (11.1 mmol/L) * Fasting plasma glucose (FPG) ≥ 126 mg/dl (7.0 mmol/L) * Plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT)⁶⁸. If any of the above test results occur, testing should be repeated on a different day to confirm the diagnosis. OR • Hemoglobin A1C (HbA1C) ≥ 6.5% ⁶⁹. 3. FAST score ≥ 0.5 and VCTE ≥ 8.0 kPa; FAST score threshold based on data from MAESTRO-NASH trial⁴²; VCTE cutpoint based on AASLD guidelines for identification of patients with significant fibrosis risk. 4. Participants without a VCTE assessment in their medical record may qualify for the study if they have a FIB-4 ≥ 1.0, which is a cutpoint based on observations of patients with T2DM in Ajmera et al³⁰, and VCTE ≥ 8.0 kPa. 5. The subject is fully informed and willing and able to perform all the procedures specified in the protocol and has signed a written informed consent to participate Exclusion criteria: 1. Presence of regular and/or excessive use of alcohol, defined as \> 30 g/day for males and \> 20 g/day for females, for a period longer than 2 years at any time in the last 10 years 2. Evidence of cirrhosis or previously known cirrhosis, based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices 3. VCTE ≥ 20 kPa 4. Platelet count ≤ 140,000 per Ml 5. Albumin \< 3.6 g/dL 6. INR \> 1.35, unless on coumadin for another indication 7. Serum creatinine \> 2.0 mg/dL 8. eGFR \< 30 mL/min/1.73 m² as defined according to the CKDEPI creatinine equation⁷⁰ 9. Use of other weight loss medications, including GLP1RA within the last 90 days 10. Greater than 10% weight loss in the prior six months 11. Known or suspected hypersensitivity to GLP1RA medications including semaglutide 12. History of bariatric surgery within the past 5 years or expected bariatric surgery 13. Evidence of other causes of chronic liver disease including: 1. Hepatitis B, as defined as presence of hepatitis B surface antigen (HBsAg). 2. Previous or current infection with Hepatitis C, as defined by presence of hepatitis C virus Ab in serum (anti-HCV Ab). 3. Autoimmune hepatitis, as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy. 4. Autoimmune cholestatic liver disorders, as defined by elevation of alkaline phosphatase and anti- mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis. 5. Wilson disease, as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease deficiency, as defined by alpha-1-antitrypsin phenotype and liver histology consistent with alpha-1-antitrypsin deficiency.

Inclusion Criteria: * Meeting the diagnostic criteria for moderate to severe depressive episode without psychotic symptoms according to the International Classification of Diseases and Related Health Problems 10th Revision (ICD-10)(The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993). * Female participants: Females in the fertile age must deliver a negative pregnancy test, or previously have been sterilized. * Female fertile participants: They must use safe contraceptive methods to be included in the study, and during the whole study. * Has given written, informed consent to the trial. Exclusion Criteria: * Inability to speak or understand the Danish language. * A current high risk of suicide (a score of 2 or more on the HAM-D-17 item 3). * A co-morbid substance dependence. * Bipolar affective disorder. * Psychotic illness. * Dementia. * Other diagnoses of organic brain disease. * The participant has any kind of implant, e.g. pacemakers or cochlear implants. * Female participants: Pregnancy

Inclusion Criteria: * Patients who provide written informed consent and who are able and willing to comply with all scheduled study visits and procedures. * Patients ≥ 18 years at the screening visit. * Ocular hypertension or glaucoma controlled with hypotensive treatment * Diagnosis of dry eye Exclusion Criteria: * Uncontrolled glaucoma with expected changes in antihypertensive treatment in the next 6 months * Changes in topical glaucoma treatment in the last 3 months * Severe dry eye requiring immediate treatment * Previous eye surgery, except cataract surgery more than 12 months ago * Laser procedures less than 6 months ago * Other concomitant ocular pathology: scarring disease of the ocular surface, uveitis, infection in the last 90 days, trauma in the last 90 days * Eyelid disorders * Use of contact lenses * Other topical treatment other than dry eye and glaucoma * Patients with a history of allergy or hypersensitivity to the study medication or any of its excipients * Modifications in systemic immunosuppressive treatment in the last 6 months * History of alcohol or drug abuse * Patients who have received an experimental drug or used an experimental medical device in the 30-day period prior to the screening visit. * Systemic pathology (cardiopulmonary pathology, connective tissue disorders, neurological or psychiatric pathology) or situation of the patient that does not allow examination (such as mental or psychomotor retardation). * Any other disease or condition that, at the discretion of the investigator, could constitute a risk to the participant or interfere with the results of the study.

Inclusion Criteria: * Stage II or III node-positive HR+/HER2- breast cancer per local laboratory assessment. * Eligible participants must be appropriate candidates for adjuvant abemaciclib, per assessment of their treating physician. * Participants must be candidates for adjuvant endocrine therapy, which may have started before or at time of entry onto the trial. Patient may be receiving adjuvant aromatase inhibitor or tamoxifen, +/- ovarian suppression. * Participants must have undergone definitive surgery of the primary breast tumor(s) within 16 months of study entry. * At least 21 days must have elapsed between last dose of chemotherapy and registration. Participants who previously received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. * At least 14 days must have elapsed between end of radiotherapy and day 1 of treatment with abemaciclib. Participants who received prior radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. No radiotherapy should be planned to occur during study therapy. * At least 14 days must have elapsed since most recent breast surgery prior to registration and patient has recovered from side effects of prior surgery. * Bilateral or multifocal/multicentric breast cancers that meet eligibility criteria are allowed. * ECOG performance status 0-1 * Men and women with any menopausal status ≥18 years of age * Adequate organ function as defined below: * Absolute neutrophil count (ANC) ≥ 1500 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Hemoglobin ≥ 8g/dL; patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion. * Bilirubin ≤ 1.5 x ULN. For patients with Gilbert syndrome, the limit is ≤ 2 x institutional ULN AND direct bilirubin within the normal range of normality. * AST/ALT ≤ 3 x institutional ULN * Premenopausal women must have a negative serum or urine pregnancy test. Pregnancy testing does not need to be pursued in female patients who are: * Age \> 60 years; or * Age \< 60 with intact uterus and amenorrhea for 12 consecutive months or more AND FSH/estradiol levels within postmenopausal range; or * Status-post bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. * Women of child-bearing potential and men with partners of childbearing potential must be willing to employ one highly effective form of nonhormonal contraception (with the exception of hormonal IUDs) or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 3 months after the last dose of abemaciclib. * Subject must be able to swallow and retain oral medication. * Ability to understand and the willingness to sign a written informed consent document. * Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires. Exclusion Criteria: * Prior treatment with any CDK4/6 inhibitor. * Patients with node-negative breast cancer are not eligible for the trial. * Concurrent therapy with other investigational agents. * Diagnosis of inflammatory breast cancer (T4d). * History of allergic reactions attributed to abemaciclib or similar chemical or biologic composition or excipients. * Participants with a history of malignancy are ineligible except in the following circumstances: --Individuals with a history of invasive breast cancer are not eligible unless they have been disease-free for a minimum of five years. * Individuals with a malignancy history other than invasive breast cancer are eligible if they have no active malignancy and are deemed by the investigator to be at low risk for recurrence of that malignancy. * Individuals with the following cancer history are eligible: adequately treated non- melanoma skin cancers, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS) of the breast, stage 1 grade 1 endometrial carcinoma. Other exceptions may exist following review with the sponsor-investigator * Serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting uncontrolled Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea) or other conditions that in the opinion of the investigator limit compliance with study requirements. * History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. * Any of the following due to teratogenic potential of the study drugs: * Pregnant women * Nursing women * Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, IUDS, surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted. * Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc). * Receipt of an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to enrollment, or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor-investigator not to be scientifically or medically compatible with this study. * Active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment) or invasive/ systemic fungal infection\\ * For patients with known HIV infection, CD4 baseline count should be evaluated: patients with a CDK count ≥ 350 cells/uL can be enrolled. Participants should be on established anti-retroviral therapy (ART) for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment. Potential pharmacological interactions of the ART with abemaciclib and endocrine therapy must be reviewed, particularly for the effects on CYP3A4. * Patients with active or chronic Hepatitis B or C are eligible provided they meet liver function laboratory criteria and cannot be on any medication with a known interaction with the study agents. * Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4, including selected herbals (e.g., hypericum) and food (e.g., grapefruit) known for pharmacological interactions, cannot be enrolled, due to interference with the dose-escalation, unless the food or supplement has been discontinued at least after an interval equivalent to 3-5 half-lives of the inhibitor.

Inclusion Criteria: * Newly diagnosed subjects with OSA that will undergo CPAP treatment. * At least 21 years of age * Best corrected vision of 20/40 or better, spherical Rx \< ± 6.0 Diopter, and cylinder \<-3.0D * Ability to follow instructions, and intent to complete all study visits Exclusion Criteria: * High Rx \>± 6.0D and cylinder \> -3.0D * Narrow angle glaucoma * History of any of the following: severe eye trauma, ocular inflammation, previous intraocular surgery except for uncomplicated cataract extraction with posterior chamber intraocular lens implantation. * Any medical or ocular condition which is not appropriate for participation in the trial (Diabetic retinopathy, and other retinal changes preventing reliable optic disc evaluation) Hypersensitivity to any component of altafluor benox

Rul-in Phase Inclusion Criteria: * Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either \>50% angiographic stenosis or any flow limiting lesion on functional evaluation) * Suspected diagnosis of difficult to control/ resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered. Rule-in Phase Exclusion Criteria: * Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase * Physiological assessment performed during first medical contact documenting preserved coronary microvascular function * Physiological assessment performed at the "first contact" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN * Acceptable blood pressure control after medical treatment optimization * Identification of secondary causes of hypertension * Renal artery anatomy not suitable for RDN * Ejection fraction below 30% * Life expectancy below 1 year * Indication to cardiac surgery * Adenosine allergy * Pregnancy * Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images. * Hemodynamic instability * Refuse to sign informed consent * Age below 18 or above 80 Study Phase Inclusion Criteria: * Having coronary microvascular dysfunction documented by invasive functional assessment (IMR\>25 and or CFR \< 2) * Fulfilling all the rule-in phase inclusion criteria without any rule-in phase exclusion criteria Study Phase Exclusion Criteria: * Refuse to sign informed consent * Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN

Inclusion Criteria: * Inclusion Criteria: ECOG Performance Status of 0-1. Early or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression). Tumor stage: II-III. Adequate hematologic and organ function. Must be willing to use an adequate method of contraception for the course of the study. Exclusion Criteria: * Has a history of breast cancer. Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Has received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months. Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death - ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated antigen-4 \[CTLA-4\]. Has a diagnosis of immunodeficiency or autoimmune diseases. Has received any form of immunosuppressive therapy within 4 weeks prior to the first dose of study treatment. Severe pulmonary or cardiac disease. Known active hepatitis C virus, or known active hepatitis B virus. History of organ or bone marrow transplantation. Pregnant or breast-feeding women. Patients who have previously received VEGFR-like small molecule tyrosine kinase inhibitors (such as famitinib, sorafenib, Sunitinib, regorafenib, etc.) (except bevacizumab); Urine routine indicated urinary protein ≥2+ and confirmed urinary protein quantity \> 1g at 24h;

Inclusion Criteria: * Newly treated female patients aged ≥18 years and ≤75 years; * ECOG score 0\~1; * Pathologically diagnosed as HER2-positive breast cancer patients with early or locally advanced tumor stage, primary tumor diameter T≥2cm or lymph node positive; * Hormone receptor status (ER and PgR) is known, where ER≥10% * Normal function of major organs: 1. The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT≥90×109/L; Hb ≥90g/L 2. Biochemical examination should meet the following standards: TBIL≤ the upper limit of normal value(ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (CockcroftGault formula); 3. Cardiac color ultrasound and echocardiography: left ventricular ejection fraction(LVEF≥55%) 4. Fridericia calibrated QT interval (QTcF) for 18-lead ECG \<470 ms; * For female patients who are not menopausal or have not been surgically sterilized: consent to abstinence or use of an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment; * Volunteer to join the study and sign the informed consent. Exclusion Criteria: * Stage IV (metastatic) breast cancer; * Inflammatory breast cancer; * Previous antitumor therapy or radiation therapy for any malignancies, excluding cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma; * Also receiving antitumor therapy in other clinical trials, including endocrine therapy, bisphosphonate therapy, or immunotherapy; * Had a major surgery not related to breast cancer in the 4 weeks prior to enrollment, or had not fully recovered from such surgery; * Serious heart disease or discomfort, including but not limited to the following: * History of heart failure or systolic dysfunction (LVEF \< 50%) * High-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \>100 bpm, significant ventricular arrhythmias (such as ventricular tachycardia), or higher-grade atrioventricular block (i.e. Mobitz II second- degree atrioventricular block or third-degree atrioventricular block * Inability to swallow, intestinal obstruction, or other factors affecting the use and absorption of the drug; * Known allergic history of the drug components of this protocol; A history of immunodeficiency, including HIV testing positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation; * Women who are pregnant or nursing, women who are fertile and have a positive baseline pregnancy test, or women of childbearing age who are unwilling to use effective contraception throughout the trial period and within 7 months after the last study medication; * Have a serious concomitant condition or other comorbid condition that interferes with planned treatment, or any other condition in which the investigator deems the patient unsuitable for participation in the study.

Inclusion Criteria: * Before patient registration, written informed consent must be given according to national and local regulations. * Participants have had histologically proven stage I-III breast cancer undergoing endocrine treatment (with or without prior chemotherapy) no more than 12 months prior to randomization. * Be between 18 and 75 years of age. * Have increased life expectancy beyond the initial 3 months post-treatment initiation. * Have the ability to understand protocol, participate in testing and willingness to sign a written informed consent. * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Exclusion Criteria: * Patients that are not willing to sign an informed consent form

Inclusion Criteria: * Age between 18 and 80 years * Patients diagnosed with Child-Turcotte-Pugh A6-B class Hepatic Cirrhosis (moderately impaired liver function) * Patients diagnosed with Hepatic Cirrhosis of viral etiology (if previous hepatitis C virus (HCV) infection they must be in Sustained Virological Response (SVR); if previous hepatitis B virus (HBV) infection they must have undetectable viral genome) * Patients diagnosed with hepatic cirrhosis of metabolic etiology * Patients diagnosed with liver cirrhosis of alcoholic etiology (non active potus) * Patients with grade 1 ascites: ascites detectable only ultrasound that can be fully mobilized or controlled with diuretic therapy associated with or without moderate dietary sodium restriction * Grade 2 ascites: ascites that leads to a moderate abdominal distension and that recurs on at least 3 occasions within a 12-month period despite sodium restriction and adequate diuretic therapy (23) * Patients diagnosed with type II diabetes mellitus defined according to 2022 American Diabetes Association (ADA) guidelines. Exclusion Criteria: * Inability to obtain informed consent * Ascites of non-cirrhotic origin * Patients diagnosed with heart failure Heart (NYHA) class =\> 2 * Patients diagnosed with acute renal failure * Patients diagnosed with chronic renal failure and glomerular filtration rate (eGFR) below 25ml/min * Patients with hepatocellular carcinoma (diagnosed according to the Barcelona criteria) or other active tumors (25) * Grade 3 ascites: ascites that causes marked distention of the abdomen and that cannot be mobilized or whose early recurrence (i.e. after large volume paracentesis) cannot be satisfactorily prevented by medical therapy * Patients diagnosed with acute Spontaneous Bacterial Peritonitis (26) * Patients diagnosed with severe hepatic encephalopathy * Patients diagnosed with autoimmune diseases on active steroid treatment * Patients diagnosed with liver cirrhosis due to storage diseases * Patients diagnosed with cirrhosis of the liver due to enzyme deficiency * Patients diagnosed with complete portal thrombosis * Patients with active sepsis * Pregnant or breastfeeding women * Patients who use drugs * Patients with active alcohol consumption

Inclusion Criteria: * All patients undergoing laparoscopic MGB surgery for morbid obesity and it's associated comorbidities Exclusion Criteria: * Patients not giving consent for the study * All patients who were undergoing a redo-procedure for recurrence were excluded from the study

Inclusion Criteria: * Eligible to receive federally-funded transition-related services in Oregon (ages 16-20 and in foster care at least 90 days after they turned age 14), * Indicated behavioral health risk. Behavioral health risk is indicated by child welfare administrative indicators of lifetime behavioral health need or service involvement (DSM diagnoses, psychotropic medication, emotional-behavioral disability, congregate care/residential placement) Exclusion Criteria: * Inability to actively participate in the intervention, including you who are: non-English speaking, significantly developmentally disabled, or where participation is otherwise contraindicated (e.g., youth is in crisis, youth is in a placement that will not allow for participation)